BRACKEN CHARLES H R

SEC source: 0001570585-24-000074 · wk-form4_1710273815.xml · nonDerivative · entry 3

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,363

F1 · shares: Class A and Class C common shares of the Issuer received by the Reporting Person pursuant to the Issuer's 2023 Annual Performance Award for employees (which was paid in part in shares), subject to applicable tax withholding.

F1 · price: Class A and Class C common shares of the Issuer received by the Reporting Person pursuant to the Issuer's 2023 Annual Performance Award for employees (which was paid in part in shares), subject to applicable tax withholding.

SEC source: 0001570585-24-000074 · wk-form4_1710273815.xml · nonDerivative · entry 2

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,646

SEC source: 0001570585-24-000074 · wk-form4_1710273815.xml · nonDerivative · entry 1

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,642

F1 · shares: Class A and Class C common shares of the Issuer received by the Reporting Person pursuant to the Issuer's 2023 Annual Performance Award for employees (which was paid in part in shares), subject to applicable tax withholding.

F1 · price: Class A and Class C common shares of the Issuer received by the Reporting Person pursuant to the Issuer's 2023 Annual Performance Award for employees (which was paid in part in shares), subject to applicable tax withholding.

SEC source: 0001570585-24-000061 · wk-form4_1709591268.xml · derivative · entry 6

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class C Common Shares · 1,046 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A common shares or Class C common shares, as the case may be.

F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A common shares or Class C common shares, as the case may be.

F2 · derivative.exercise_date: The RSUs vested in full on March 1, 2024.

F2 · derivative.expiration_date: The RSUs vested in full on March 1, 2024.

SEC source: 0001570585-24-000061 · wk-form4_1709591268.xml · derivative · entry 5

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Shares · 523 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A common shares or Class C common shares, as the case may be.

F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A common shares or Class C common shares, as the case may be.

F2 · derivative.exercise_date: The RSUs vested in full on March 1, 2024.

F2 · derivative.expiration_date: The RSUs vested in full on March 1, 2024.

SEC source: 0001570585-24-000061 · wk-form4_1709591268.xml · nonDerivative · entry 4

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,990

SEC source: 0001570585-24-000061 · wk-form4_1709591268.xml · nonDerivative · entry 3

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,482

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A common shares or Class C common shares, as the case may be.

SEC source: 0001570585-24-000061 · wk-form4_1709591268.xml · nonDerivative · entry 2

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,269

SEC source: 0001570585-24-000061 · wk-form4_1709591268.xml · nonDerivative · entry 1

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,515

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A common shares or Class C common shares, as the case may be.

SEC source: 0001570585-23-000400 · wk-form4_1695414745.xml · nonDerivative · entry 2

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,436

F2 · price: The price reflects a weighted average of sales made at prices ranging from $19.525 to $19.73. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, information regarding the number of shares sold at each separate price.

SEC source: 0001570585-23-000400 · wk-form4_1695414745.xml · nonDerivative · entry 1

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,992

F1 · price: The price reflects a weighted average of sales made at prices ranging from $18.27 to $18.28. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, information regarding the number of shares sold at each separate price.

SEC source: 0001570585-23-000260 · wk-form4_1687898509.xml · nonDerivative · entry 1

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,013

F1 · price: The price reflects a weighted average of sales made at prices ranging from $17.38 to $17.485. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, information regarding the number of shares sold at each separate price.

SEC source: 0001570585-23-000157 · wf-form4_168314746541689.xml · derivative · entry 10

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,022

Underlying: Class C Ordinary Shares · 28,022 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

F3 · derivative.exercise_date: The RSUs vest in three equal annual installments commencing on May 1, 2022.

F3 · derivative.expiration_date: The RSUs vest in three equal annual installments commencing on May 1, 2022.

SEC source: 0001570585-23-000157 · wf-form4_168314746541689.xml · derivative · entry 9

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,011

Underlying: Class A Ordinary Shares · 14,011 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

F3 · derivative.exercise_date: The RSUs vest in three equal annual installments commencing on May 1, 2022.

F3 · derivative.expiration_date: The RSUs vest in three equal annual installments commencing on May 1, 2022.

SEC source: 0001570585-23-000157 · wf-form4_168314746541689.xml · derivative · entry 8

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class C Ordinary Shares · 49,326 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

F2 · derivative.exercise_date: The RSUs vest in three equal annual installments commencing on May 1, 2021.

F2 · derivative.expiration_date: The RSUs vest in three equal annual installments commencing on May 1, 2021.

SEC source: 0001570585-23-000157 · wf-form4_168314746541689.xml · derivative · entry 7

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 24,664 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

F2 · derivative.exercise_date: The RSUs vest in three equal annual installments commencing on May 1, 2021.

F2 · derivative.expiration_date: The RSUs vest in three equal annual installments commencing on May 1, 2021.

SEC source: 0001570585-23-000157 · wf-form4_168314746541689.xml · nonDerivative · entry 6

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,013

SEC source: 0001570585-23-000157 · wf-form4_168314746541689.xml · nonDerivative · entry 5

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 138,368

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

SEC source: 0001570585-23-000157 · wf-form4_168314746541689.xml · nonDerivative · entry 4

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,346

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

SEC source: 0001570585-23-000157 · wf-form4_168314746541689.xml · nonDerivative · entry 3

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,992

SEC source: 0001570585-23-000157 · wf-form4_168314746541689.xml · nonDerivative · entry 2

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,171

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

SEC source: 0001570585-23-000157 · wf-form4_168314746541689.xml · nonDerivative · entry 1

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,160

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

SEC source: 0001570585-23-000136 · wf-form4_168262921026442.xml · derivative · entry 16

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,862

Underlying: Class C Ordinary Shares · 156,862 shares

Expires 2028-05-01

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable.

SEC source: 0001570585-23-000136 · wf-form4_168262921026442.xml · derivative · entry 15

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class C Ordinary Shares · 156,862 shares

Expires 2025-05-01

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable.

SEC source: 0001570585-23-000136 · wf-form4_168262921026442.xml · derivative · entry 14

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,916

Underlying: Class C Ordinary Shares · 113,916 shares

Expires 2027-05-01

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable.

SEC source: 0001570585-23-000136 · wf-form4_168262921026442.xml · derivative · entry 13

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class C Ordinary Shares · 113,916 shares

Expires 2024-05-01

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable.

SEC source: 0001570585-23-000136 · wf-form4_168262921026442.xml · derivative · entry 12

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 333,334

Underlying: Class C Ordinary Shares · 333,334 shares

Expires 2027-02-21

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable.

SEC source: 0001570585-23-000136 · wf-form4_168262921026442.xml · derivative · entry 11

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class C Ordinary Shares · 333,334 shares

Expires 2024-02-21

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable.

SEC source: 0001570585-23-000136 · wf-form4_168262921026442.xml · derivative · entry 10

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,072

Underlying: Class C Ordinary Shares · 121,072 shares

Expires 2026-05-01

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable.

SEC source: 0001570585-23-000136 · wf-form4_168262921026442.xml · derivative · entry 9

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class C Ordinary Shares · 121,072 shares

Expires 2023-05-01

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable.

SEC source: 0001570585-23-000136 · wf-form4_168262921026442.xml · derivative · entry 8

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,431

Underlying: Class A Ordinary Shares · 78,431 shares

Expires 2028-05-01

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable.

SEC source: 0001570585-23-000136 · wf-form4_168262921026442.xml · derivative · entry 7

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 78,431 shares

Expires 2025-05-01

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable.

SEC source: 0001570585-23-000136 · wf-form4_168262921026442.xml · derivative · entry 6

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,958

Underlying: Class A Ordinary Shares · 56,958 shares

Expires 2027-05-01

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable.

SEC source: 0001570585-23-000136 · wf-form4_168262921026442.xml · derivative · entry 5

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 56,958 shares

Expires 2024-05-01

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable.

SEC source: 0001570585-23-000136 · wf-form4_168262921026442.xml · derivative · entry 4

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 166,666

Underlying: Class A Ordinary Shares · 166,666 shares

Expires 2027-02-21

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable.

SEC source: 0001570585-23-000136 · wf-form4_168262921026442.xml · derivative · entry 3

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 166,666 shares

Expires 2024-02-21

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable.

SEC source: 0001570585-23-000136 · wf-form4_168262921026442.xml · derivative · entry 2

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,536

Underlying: Class A Ordinary Shares · 60,536 shares

Expires 2026-05-01

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable.

SEC source: 0001570585-23-000136 · wf-form4_168262921026442.xml · derivative · entry 1

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 60,536 shares

Expires 2023-05-01

F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply.

F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable.

SEC source: 0001570585-23-000086 · wf-form4_168003942909579.xml · derivative · entry 4

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 288,350

Underlying: Class C Ordinary Shares · 288,350 shares

Expires 2033-03-24

F3 · derivative.exercise_date: The Share Appreciation Rights vest in three equal annual installments commencing on May 1, 2024.

SEC source: 0001570585-23-000086 · wf-form4_168003942909579.xml · derivative · entry 3

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 144,175

Underlying: Class A Ordinary Shares · 144,175 shares

Expires 2033-03-24

F3 · derivative.exercise_date: The Share Appreciation Rights vest in three equal annual installments commencing on May 1, 2024.

SEC source: 0001570585-23-000086 · wf-form4_168003942909579.xml · derivative · entry 2

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 106,840

Underlying: Class C Ordinary Shares · 106,840 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

F2 · derivative.exercise_date: The RSUs vest in three equal annual installments commencing on May 1, 2024.

F2 · derivative.expiration_date: The RSUs vest in three equal annual installments commencing on May 1, 2024.

SEC source: 0001570585-23-000086 · wf-form4_168003942909579.xml · derivative · entry 1

BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,420

Underlying: Class A Ordinary Shares · 53,420 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be.

F2 · derivative.exercise_date: The RSUs vest in three equal annual installments commencing on May 1, 2024.

F2 · derivative.expiration_date: The RSUs vest in three equal annual installments commencing on May 1, 2024.

SEC source: 0001712184-23-000097 · wf-form4_167951793306326.xml · derivative · entry 2

BRACKEN CHARLES H R · CIK 0001091974 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,438

Underlying: Class C Common Shares · 12,438 shares

Expires 2024-03-15

F1 · derivative.exercise_price: Each Restricted Share Unit represents a right to receive one share of the Issuer's Class A common shares or Class C common shares, as the case may be, at settlement.

F1 · price: Each Restricted Share Unit represents a right to receive one share of the Issuer's Class A common shares or Class C common shares, as the case may be, at settlement.

SEC source: 0001712184-23-000097 · wf-form4_167951793306326.xml · derivative · entry 1

BRACKEN CHARLES H R · CIK 0001091974 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,219

Underlying: Class A Common Shares · 6,219 shares

Expires 2024-03-15

F1 · derivative.exercise_price: Each Restricted Share Unit represents a right to receive one share of the Issuer's Class A common shares or Class C common shares, as the case may be, at settlement.

F1 · price: Each Restricted Share Unit represents a right to receive one share of the Issuer's Class A common shares or Class C common shares, as the case may be, at settlement.

SEC source: 0001712184-23-000066 · wf-form4_167908484063133.xml · derivative · entry 6

BRACKEN CHARLES H R · CIK 0001091974 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class C Common Shares · 10,416 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit represents a right to receive one share of the Issuer's Class A common shares or Class C common shares, as the case may be, at settlement.

F1 · price: Each Restricted Share Unit represents a right to receive one share of the Issuer's Class A common shares or Class C common shares, as the case may be, at settlement.

F2 · derivative.exercise_date: The Restricted Share Units vest in full on March 15, 2023.

F2 · derivative.expiration_date: The Restricted Share Units vest in full on March 15, 2023.

SEC source: 0001712184-23-000066 · wf-form4_167908484063133.xml · derivative · entry 5

BRACKEN CHARLES H R · CIK 0001091974 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Shares · 5,208 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit represents a right to receive one share of the Issuer's Class A common shares or Class C common shares, as the case may be, at settlement.

F1 · price: Each Restricted Share Unit represents a right to receive one share of the Issuer's Class A common shares or Class C common shares, as the case may be, at settlement.

F2 · derivative.exercise_date: The Restricted Share Units vest in full on March 15, 2023.

F2 · derivative.expiration_date: The Restricted Share Units vest in full on March 15, 2023.

SEC source: 0001712184-23-000066 · wf-form4_167908484063133.xml · nonDerivative · entry 4

BRACKEN CHARLES H R · CIK 0001091974 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,404

SEC source: 0001712184-23-000066 · wf-form4_167908484063133.xml · nonDerivative · entry 3

BRACKEN CHARLES H R · CIK 0001091974 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,528

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit represents a right to receive one share of the Issuer's Class A common shares or Class C common shares, as the case may be, at settlement.

SEC source: 0001712184-23-000066 · wf-form4_167908484063133.xml · nonDerivative · entry 2

BRACKEN CHARLES H R · CIK 0001091974 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,323

SEC source: 0001712184-23-000066 · wf-form4_167908484063133.xml · nonDerivative · entry 1

BRACKEN CHARLES H R · CIK 0001091974 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,385

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit represents a right to receive one share of the Issuer's Class A common shares or Class C common shares, as the case may be, at settlement.